4.7 Meeting Abstract

Two phase 1 studies of MPC-6827, a novel vascular disrupting agent (VDA), in patients with advanced solid tumors and CNS metastases

Journal

JOURNAL OF CLINICAL ONCOLOGY
Volume 25, Issue 18, Pages -

Publisher

AMER SOC CLINICAL ONCOLOGY
DOI: 10.1200/JCO.2006.07.8170

Keywords

-

Categories

Ask authors/readers for more resources

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available